欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (6): 700-702.

• 药物治疗学 • 上一篇    下一篇

23价肺炎球菌多糖疫苗和流行性感冒疫苗防治老年慢性肺病急性发作的研究

杜坚宗1, 刘小利2, 赵恬1, 顾亮1, 钦光跃1   

  1. 1浙江医院呼吸内科,杭州 310013,浙江;
    2浙江医院神经内科,杭州 310013,浙江
  • 收稿日期:2012-03-05 修回日期:2012-05-29 出版日期:2012-06-26 发布日期:2012-06-25
  • 通讯作者: 钦光跃,男,硕士,主任医师,硕士研究生导师,主要从事慢性阻塞性肺疾病、睡眠障碍及肺癌研究。Tel: 13306518552 E-mail: hzqgy@126.com
  • 作者简介:杜坚宗,男,硕士,主治医师,主要从事慢性阻塞性肺疾病、睡眠障碍基础及临床研究。Tel: 13251016992 E-mail: djzdjz@163.com
  • 基金资助:
    浙江省医药卫生科学研究基金(2009B007)

Additive effect of 23-valent pneumococcal polysaccharide vaccine and influenza vaccine on acute exacerbation in older patients with chronic lung disease

DU Jian-zong1, LIU Xiao-li2, ZHAO Tian1, GU Liang1, QIN Guang-yue1   

  1. 1Department of Respiratory, Zhejiang Hospital, Hangzhou 310013, Zhejiang, China;
    2Department of Neurology, Zhejiang Hospital, Hangzhou 310013, Zhejiang, China
  • Received:2012-03-05 Revised:2012-05-29 Online:2012-06-26 Published:2012-06-25

摘要: 目的: 评价老年慢性肺病人群联合接种 23 价肺炎球菌多糖疫苗和流行性感冒疫苗, 预防慢性肺病急性发作的效果。方法: 选取2008年10月到2009年3月的稳定期老年慢性肺病患者192例。随机分为接种23价肺炎球菌多糖疫苗和流行性感冒疫苗的试验组97例和接种流行性感冒疫苗的对照组95例。在基线调查的基础上,接种后1年内随访两组慢性肺病第一次急性发作时间情况。结果: 试验组急性发作的发生率 53.6%(52/97)低于对照组 72.6%(69/95)(χ2=6.659,P=0.010)。接种23价肺炎球菌多糖疫苗和流行性感冒疫苗能减少慢性肺病急性发作的发生率,其保护效率为 26.2%。两组病死率相近,分别为 8.2%(8/97)和 11.6%(11/95)(χ2=0.597,P=0.440)。Kaplan-Meier生存函数发现试验组慢性肺病急性发作未发生率低于对照组(log-rank检验,χ2=8.065,P=0.005)。结论: 联合接种 23 价肺炎球菌多糖疫苗和流行性感冒疫苗能减少慢性肺病急性发作的发生, 具有一定的保护效力。

关键词: 23价肺炎球菌多糖疫苗, 流行性感冒疫苗, 老年人, 慢性肺病, 急性发作

Abstract: AIM: To assess the effectiveness of 23-valent penumococcal polysaccharide vaccine (PV) and influenza vaccine (IV) for preventing acute exacerbation in older patients with chronic lung diseases (CLD). METHODS: An open-label, randomized, controlled study among 192 older patients with CLD in a stable condition over a 1-year period was designed. Subjects were randomly assigned to a PV+ IV group (n=97) or an IV group (n=95). On base line survey, both groups were followed up one year about the time to the first episode of acute exacerbation after the enrollment in this study. RESULTS: The number of older patients with CLD experiencing infectious acute exacerbation(χ2=6.659,P=0.010), but not death(χ2=0.597,P=0.440), was significantly lower in the PV+ IV group compared with the IV group. In older patients with CLD, the Kaplan-Meier survival curves demonstrated a significant difference for infectious acute exacerbation(log-rank test,χ2=8.065,P=0.005) between the two groups. CONCLUSION: This study demonstrated an additive effect of PV in combination with IV on infectious acute exacerbation of older patients with CLD.

Key words: 23-valent penumococcal polysaccharide vaccine, Influenza vaccine, Elderly, Chronic lung diseases, Acute exacerbation

中图分类号: